Business Wire - May 19, 2003

"We welcome the intense peer review that preceded the publication of these results," commented John N. Bonfiglio, Ph.D., chief executive officer of The Immune Response Corporation. "Our newly established Scientific Advisory Board will use this data to help design future trials of REMUNE(R) in order to help accomplish our mission of establishing REMUNE(R)'s clinical benefit."

Specifically, the trial -- which was investigator-initiated and designed, double blinded and placebo-controlled -- demonstrated the induction of HIV-specific lymphocyte proliferation in all the chronically infected subjects who received REMUNE(R) and in none of those who received placebo. A total of 10 subjects participated, all of whom had viral loads controlled to less than 500 copies/ml for at least six months and CD4 cell counts of greater than 250 cells/mrn before starting ART.

While The Immune Response Corporation provided financial support and some reagents for the trial, the investigators generated, maintained and analyzed all related data using rigorous, prospectively defined criteria. The Immune Response Corporation did not participate in the preparation of the manuscript.

Trial data was originally presented at the XIV International AIDS Conference in Barcelona, Spain.

About The Immune Response Corporation and REMUNE(R)

Co-founded by medical pioneer Dr. Jonas Salk and headquartered in Carlsbad, California, The Immune Response Corporation is a biopharmaceutical company dedicated to treating HIV and AIDS through the development of REMUNE(R). REMUNE(R) is an immune-based therapeutic vaccine designed to induce an HIV-specific immune response and boost the body's natural defense mechanisms in order to slow the virus' progression. REMUNE(R) is comprised of HIV that has been chemically killed and inactivated so that it is non-infectious. During the inactivation process, the HIV outer envelope, which is prone to rapid mutations, is removed. REMUNE(R) is then emulsified in Incomplete Freund's Adjuvant, an agent that elicits a more potent immune response by drawing the immune system's attention to the inactivated virus.

HIV, the human immunodeficiency virus, is the virus that causes AIDS, a condition that slowly destroys the body's immune system, making it vulnerable to infections. More than 60 million people have been infected with HIV since it was first recognized in 1981. Today, 40 million people around the world are living with HIV.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE(R), the uncertainty of successful completion of any such clinical trials, whether REMUNE(R) will be effective as either a preventive or therapeutic vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE(R) in preclinical trials. These risks, among others, are set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2002, and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

REMUNE(R) is a registered trademark of The Immune Response Corporation.

CONTACT: The Immune Response Corporation

Sara Jones (media), 213/893-7300, Cell: 818/326-1871

or

Kathy Lane (investors), 760/771-2236, Fax: 760/771-2140

SOURCE: The Immune Response Corporation

030519
BW030504

Copyright © 2003 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .